GlassScriptPhysician profile
Danielle L Giddins
NPI 1922082577
$4,728.67
in general payments reported to CMS, 2019-2025
31 companies · $1,056 in 2025
The $1,056 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $681 · 2020: $123 · 2021: $390 · 2022: $744 · 2023: $871 · 2024: $863 · 2025: $1,056.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,788 · Education: $1.77.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,787.99 |
| Education | $1.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $760.32 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $454.40 | 2019-2025 | Evenity, Prolia, Repatha |
| Abbvie INC. | $448.50 | 2021-2025 | |
| Pfizer INC. | $431.47 | 2019-2025 | |
| Glaxosmithkline, LLC. | $428.86 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Lilly USA, LLC | $424.83 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $236.31 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Merck Sharp & Dohme LLC | $190.69 | 2019-2025 | Gardasil 9, Vaxneuvance, Capvaxive |
| Astellas Pharma US INC | $150.84 | 2019-2024 | Veozah |
| Abbott Laboratories | $146.63 | 2022-2025 | Freestyle Libre 3, Proclaim |
| Boehringer Ingelheim Pharmaceuticals, INC. | $141.68 | 2019-2023 | Jardiance |
| Exact Sciences Corporation | $108.00 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Novartis Pharmaceuticals Corporation | $98.09 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $86.28 | 2024-2025 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $84.45 | 2022-2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $68.54 | 2021-2024 | Camzyos |
| Kowa Pharmaceuticals America, INC. | $65.23 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $52.66 | 2023-2025 | Rexulti |
| Biohaven Pharmaceutical Holding Company LTD. | $48.23 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $41.68 | 2022 | |
| Daiichi Sankyo INC. | $39.56 | 2021-2022 | |
| Aimmune Therapeutics, INC. | $36.38 | 2025 | Vowst |
| Phathom Pharmaceuticals, INC. | $29.53 | 2024-2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $28.69 | 2019 | |
| Allergan, INC. | $23.40 | 2019 | |
| Biomarin Pharmaceutical INC. | $19.49 | 2024 | Voxzogo 1.2mg |
| Biogen, INC. | $19.15 | 2024 | Spinraza |
| Lundbeck LLC | $18.75 | 2021 | |
| Amarin Pharma, INC. | $18.35 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $15.50 | 2021 | |
| Eisai INC. | $12.18 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Giddins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.